All treatment groups in Vertex Pharmaceuticals Inc.’s phase II study of the non-opioid VX-548 showed meaningful reductions in pain from baseline in treating diabetic peripheral neuropathy (DPN), pointing the company toward pivotal phase III studies and prompting analysts to applaud enthusiastically.
Hoba Therapeutics Raises EUR 23 Million In A Series A To Advance New Drug Candidate Against Chronic Neuropathic Pain menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Voice Biometrics Market Size to Reach USD 14.13 Billion in 2032 | Emergen Research sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.
Opioid drugs are prescribed to relieve severe pain and are highly addictive. Some key products include oxycodone, hydrocodone, codeine, morphine etc. .